Cefprozil is a second-generation cephalosporin antibiotic. It can be used to treat ear infections, skin infections, and other bacterial infections.. Reference standards of Cefprozil API, and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below
Cefprozil
Catalogue No.:PA 03 91000
CAS :
Molecular Formula : C18H19N3O5S
Molecular Weight : 389.43
Cefprozil-d4 (E/Z mixture)
Catalogue No.:PA STI 018440
Molecular Formula : C18H15D4N3O5S
Molecular Weight : 393.45
Cefprozil (1098062)
Catalogue No.:PA USP1098062
Molecular Formula : NA
Molecular Weight : NA
Cefprozil (Z)-Isomer (1098050)
Catalogue No.:PA USP1098050
Cefprozil (E)-Isomer (1098049)
Catalogue No.:PA USP1098049
Cefprozil Related Compound H ((6R,7R)-7-{(R)-2-[(R)-2-amino-2-(4-hydroxyphenyl)acetamido]-2-(4-hydr (1098016)
Catalogue No.:PA USP1098016
Cefprozil Related Compound K (3-(5-ethyl-7-oxo-2,4,5,7-tetrahydro-1H-furo[3,4-d][1,3]thiazin-2-yl)- (1098038)
Catalogue No.:PA USP1098038
Cefprozil Related Compound D ((6R,7R)-7-amino-8-oxo-3-[(Z)-prop-1-enyl]-5-thia-1-azabicyclo[4.2.0]o (1097986)
Catalogue No.:PA USP1097986
Cefprozil L-Epimer ((6R,7R)-7-[(S)-2-amino-2-(4-hydroxyphenyl)acetamido]-8-oxo-3-[(Z)-prop-1-enyl]- (1097997)
Catalogue No.:PA USP1097997
Cefprozil impurity A (Y0001372)
Catalogue No.:PA EPY0001372
Cefprozil (Y0001371)
Catalogue No.:PA EPY0001371
Cefprozil for peak identification (Y0001367)
Catalogue No.:PA EPY0001367
Cefprozil impurity mixture (Y0001368)
Catalogue No.:PA EPY0001368
N-Carbamoyl-D-p-hydroxyphenylglycine
Catalogue No.:PA 03 0911000
Molecular Formula : C9H10N2O4
Molecular Weight : 210.19
Methyl (R)-2-amino-2-(4-methoxyphenyl)acetate Hydrochloride
Catalogue No.:PA 03 0911001
Molecular Formula : C10H14ClNO3
Molecular Weight : 231.68
(6R,7R)-7-Amino-8-oxo-3-((Z)-prop-1-en-1-yl)-5-thia-1-azabicyclo[4.2.0]oct-3-ene-2-carboxylic Acid
Catalogue No.:PA 03 0911002
Molecular Formula : C10H12N2O3S
Molecular Weight : 240.28
I accept terms and conditions
Message sent successfully!! We will get back to you shortly ....
